A B S T R AC T
The European Best Practice Guideline group (EBPG) issued guidelines on the evaluation and selection of kidney donor and kidney transplant candidates, as well as post-transplant recipient care, in the year 2000 and 2002. The new European Renal Best Practice board decided in 2009 that these guidelines needed updating. In order to avoid duplication of efforts with kidney disease improving global outcomes, which published in 2009 clinical practice guidelines on the post-transplant care of kidney transplant recipients, we did not address these issues in the present guidelines.
The guideline was developed following a rigorous methodological approach: (i) identification of clinical questions, (ii) prioritization of questions, (iii) systematic literature review and critical appraisal of available evidence and (iv) formulation of recommendations and grading according to Grades of Recommendation Assessment, Development, and Evaluation (GRADE). The strength of each recommendation is rated 1 or 2, with 1 being a 'We recommend' statement, and 2 being a 'We suggest' statement. In addition, each statement is assigned an overall grade for the quality of evidence: A (high), B (moderate), C (low) or D (very low). The guideline makes recommendations for the evaluation of the kidney transplant candidate as well as the potential deceased and living donor, the immunological work-up of kidney donors and recipients and perioperative recipient care.
All together, the work group issued 112 statements. There were 51 (45%) recommendations graded '1', 18 (16%) were graded '2' and 43 (38%) statements were not graded. There were 0 (0%) recommendations graded '1A', 15 (13%) were '1B', 19 (17%) '1C' and 17 (15%) '1D'. None (0%) were graded '2A', 1 (0.9%) was '2B ', 8 (7%) were '2C' and 9 (8%) '2D'. Limitations of the evidence, especially the lack of definitive clinical outcome trials, are discussed and suggestions are provided for future research.
We present here the complete recommendations about the evaluation of the kidney transplant candidate as well as the potential deceased and living donor, the immunological work-up of kidney donors and recipients and the perioperative recipient care. We hope that this document will help caregivers to improve the quality of care they deliver to patients. The full version with methods, rationale and references is published in Nephrol Dial Transplant (2013) 28: i1-i71; doi: 10.1093/ndt/ gft218 and can be downloaded freely from http://www. oxfordjournals.org/our_journals/ndt/era_edta.html.
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I N T RO D U C T I O N
Caring for kidney transplant recipients (KTRs) requires specialized knowledge in areas as varied as nephrology, immunology, pharmacology, endocrinology, infectious disease and cardiology. In this context of increasing complexity coupled with an exponential growth in the medical literature, clinical practice guidelines (CPGs) aim at helping clinicians and other caregivers to deliver evidence-based medicine and thereby, to improve patient outcomes. Furthermore, guidelines also help to expose gaps in our knowledge and thereby suggest areas where additional research is needed. This guideline was developed following a rigorous methodological approach: (i) identification and selection of a representative work group, consisting of experts in transplantation (nephrologists, surgeons and immunologists) and guideline methodologists; (ii) identification of clinical questions; (iii) prioritization of questions; (iv) systematic literature review and critical appraisal of available evidence; (v) formulation of recommendations and grading according to GRADE; (vi) comparison to existing guidelines, when available and (vii) suggestions for future research. The GRADE system allows provision of guidance even if the evidence base is weak, but makes the quality of the available evidence transparent and explicit. The strength of each recommendation is rated 1 or 2, with 1 being a 'We recommend' statement implying that most patients should receive the course of action, and 2 being a 'We suggest' statement implying that different choices will be appropriate for different patients with the suggested course of action being a reasonable choice. In addition, each statement is assigned an overall grade for the quality of evidence: A (high), B (moderate), C (low) or D (very low). Although there are reasons other than quality of evidence to make a grade 1 or 2 recommendation, in general, there is a correlation between the quality of overall evidence and the strength of the recommendation. Even if the evidence is weak, clinicians still need to make clinical decisions in their daily practice, and they often ask 'what do the experts do in this setting'? Therefore, the European Renal Best Practice (ERBP) board opted to give guidance, even if evidence was weak or non-existent, which unfortunately is often the case in nephrology. The draft guidelines were submitted for review to selected European experts, all European Renal AssociationEuropean Dialysis and Transplantation Association (ERA-EDTA) members and reviewers selected by the European Society of Organ Transplantation and The Transplantation Society. Where appropriate, changes based on these comments were made in the final document. We felt this is an important step in the development of guidelines, as it fuelled the base of expertise that enhanced the overall quality of the guideline. We owe a special debt of gratitude to all those who took time out of their busy schedules to share their comments with us. They have been instrumental in improving the final guidelines.
We hope that this document will help caregivers to improve the quality of care they deliver to patients. 
N D T P E R S P E C T I V E S
T r a n s p l a n t g u i d e l i n e s (2) their CD4 + T-cell counts are >200/µL and have been stable during the previous 3 months.
(3) HIV RNA was undetectable during the previous 3 months.
(4) no opportunistic infections occurred during the previous 6 months.
(5) they show no signs compatible with progressive multifocal leukoencephalopathy, chronic intestinal cryptosporidiosis or lymphoma. (1C)
1.2.3. We suggest that the most appropriate anti-retroviral therapy should be discussed before transplantation with the infectious diseases team in order to anticipate potential drug interactions after transplantation. (Ungraded Statement)
1.3 Is there a role for immunization against herpes varicella zoster prior to kidney transplantation?
1.3.1. We recommend immunization against varicella-zoster virus in all paediatric and adult patients negative for antivaricella-zoster antibodies, preferably when they are still waitlisted. (1D)
1.4 Should haemolytic uraemic syndrome (HUS) as underlying cause of end-stage kidney disease preclude wait-listing for transplantation and does it influence graft and patient survival post-transplantation?
1.4.1. We recommend that typical, proven shiga-toxin E. coliassociated haemolytic uraemic syndrome (HUS) is not contra-indication to transplantation from either deceased or living donors. (1B) 1.4.2. We suggest considering kidney transplantation as an acceptable option (i) in kidney transplant candidates with atypical HUS and a proven membrane cofactor protein (MCP) mutation, and (ii) in those displaying anti-complement factor H (CFH) auto-antibodies. (Ungraded Statement)
1.4.3 We suggest that kidney transplantation in patients with atypical HUS should only be undertaken in centres with experience in managing this condition and where appropriate therapeutic interventions are available. (Ungraded Statement) 1.4.4. We do not recommend living donation from a genetically related donor in patients who are suspected to have atypical HUS as their underlying kidney disease unless the responsible mutation has been conclusively excluded in the donor. (1D) 1.4.5. We recommend evaluating the potential of living donation from a genetically unrelated donor to a recipient with atypical HUS on a case-by-case basis. It should only be considered after appropriate counselling of the recipient and donor on the risk of disease recurrence in the transplanted graft. (Ungraded Statement)
1.5 Should focal segmental glomerulosclerosis (FSGS) as underlying cause of end-stage kidney disease preclude waitlisting for transplantation and does it influence graft and patient survival post-transplantation?
1.5.1. We recommend that primary focal segmental glomerulosclerosis per se is not a contra-indication to kidney transplantation from either a living or a deceased donor. (1D)
1.5.2. We recommend informing the recipient and in living donation, the potential donor, about the risk of recurrence of focal segmental glomerulosclerosis in the graft. (Ungraded Statement)
1.5.3. We recommend that when a first graft has been lost from recurrent focal segmental glomerulosclerosis, a second graft from either a deceased or a living donor should only be transplanted after an individual risk/benefit assessment and careful counselling of the recipient and potential donor in the case of living donation. (Ungraded Statement)
1.5.4. We suggest using an updated management protocol in cases of recurrent focal segmental glomerulosclerosis.
(Ungraded Statement)
1.5.5. We suggest that children with steroid-resistant nephrotic syndrome undergo appropriate genotyping before wait-listing them for kidney transplantation. (Ungraded Statement)
1.6 Does pre-transplant alcohol and drug abuse in patients influence patient or graft survival?
1.6.1. We recommend that women who drink >40 g and men who drink >60 g of alcohol per day stop or reduce their alcohol consumption to below these levels. (1D) 2.3.1. We do not recommend routine typing for major histocompatibility complex class I related chain-A (MICA) and other non-HLA antigens in either the recipient or donor.
T r a n s p l a n t g u i d e l i n e s 3.1.2. We suggest that in cadaveric donors where there is uncertainty about the quality of the kidneys, the decision to either discard the kidneys, or use them as a dual or a single transplant, is based on a combination of the clinical evaluation and history of the recipient and donor, and when available, a standardized assessment of a pre-transplant donor biopsy. (2D) 3.1.3. We recommend that before a kidney from a paediatric donor is discarded due to low donor age it is deemed unsuitable for single transplantation in an adult recipient, en bloc transplantation is considered. (1B) 3.1.4. We suggest that the option of using kidneys for en bloc transplantation is always considered for donors weighing less than 10 kg. (1D) 3.2. Which perfusion solution is best suited for kidney preservation in recipients of living donation? Which perfusion solution is best suited for kidney preservation in recipients of deceased kidney donation?
3.2.1. There is insufficient evidence to favour a particular preservation solution for kidneys that carry a low risk of delayed graft function. (Ungraded Statement) 3.2.2. We recommend not using Eurocollins as a preservation solution for kidneys that carry a high risk of delayed graft function (long projected cold ischaemia time, extended criteria donors). (1B) 3.3. Is machine perfusion superior to standard perfusion?
3.3.1. There are conflicting data regarding the generalizability of the benefit of machine perfusion over static cold storage. Until further evidence emerges, no firm recommendation for the use of machine perfusion in preference to cold storage can be made. (Ungraded Statement)
T r a n s p l a n t g u i d e l i n e s 3.4. Is there a critical cold ischaemia time beyond which a donated organ should be discarded?
3.4.1. We suggest that cold ischaemia time be kept as short as possible. (2D) 3.4.2. We recommend keeping cold ischaemia time below 24 hours when transplanting kidneys from donors after brain death. (1B) 3.4.3. We recommend keeping cold ischaemia time to less than 12 hours when using kidneys from donors after cardiac death. (1D) 3.4.4. We recommend that the decision to use donor kidneys with a cold ischaemia time of more than 36 hours be made on a case per case basis. (1D) 3.5. On which criteria should we select living kidney donors to optimize the risk/benefit ratio of their donation?
General remarks
3.5.1. We recommend encouraging living kidney donors to exercise on a regular basis and when relevant, to lose weight and stop smoking. (1C) 3.5.2. We recommend that the individual risk of donation should be carefully discussed with the donor, taking into account the situation of both donor and recipient. Ideally, this should be done using standardized checklists to ensure all items are discussed. (Ungraded Statement) 3.5.3. We suggest that the donor be evaluated by an independent physician who is not part of the transplant team and is not involved in the daily care of the recipient, and when possible, by a psychologist. (Ungraded Statement) 3.5.4. We recommend that the process of donation is stopped should any doubt on donor safety arise, especially in younger donors, or when the benefit for the recipient is limited.
(Ungraded Statement) 3.5.5. We recommend that the simultaneous presence of more than one risk factor (hypertension, obesity, proteinuria, impaired glucose tolerance, haematuria) precludes donation.
(Ungraded Statement) 4.5.1. We do not recommend routinely using low-molecularweight heparin, unfractionated heparin or aspirin before transplantation to prevent graft thrombosis. (1B) 4.6. In renal transplant recipients, what are the effects of using a JJ stent at the time of operation on renal outcomes?
4.6.1. We recommend prophylactic JJ stent placement as a routine surgical practice in adult kidney transplantation.
4.6.2. We suggest that if a JJ stent is in place, cotrimoxazole is given as antibiotic prophylaxis. (2D) 4.6.3. We suggest removing the JJ stent within 4-6 weeks.
(Ungraded Statement) 4.7. What is the optimal post-operative time for removal of the indwelling bladder catheter in kidney transplant recipients?
4.7.1. We suggest removing the urinary bladder catheter as soon as possible after transplantation, balancing the risk of urinary leak against that of urinary tract infection. (2D) 4.7.2. We recommend monitoring adverse event rates (urinary tract infection, urinary leakage) in each centre, to inform the decision over when to remove the indwelling bladder catheter. (1D) 
